Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases
Identifieur interne : 000930 ( Pmc/Curation ); précédent : 000929; suivant : 000931Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases
Auteurs : Marcia A. Blackman [États-Unis] ; Mark A. Marchionni [États-Unis] ; John Gilly [États-Unis] ; Matthew Hepburn [États-Unis] ; Bruce L. Innis [États-Unis] ; Alan D. T. Barrett [États-Unis] ; Kent E. Kester [États-Unis] ; John R. Mascola [États-Unis] ; James F. Cummings [États-Unis] ; Thomas P. Monath [États-Unis] ; M. Cristina Cassetti [États-Unis] ; Jerome H. Kim [Corée du Sud] ; Melanie Saville [Royaume-Uni] ; Stephen J. Thomas [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2019.
Abstract
Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.
Url:
DOI: 10.1016/j.vaccine.2019.08.061
PubMed: 31500964
PubMed Central: 7131820
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000930
Links to Exploration step
PMC:7131820Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases</title><author><name sortKey="Blackman, Marcia A" sort="Blackman, Marcia A" uniqKey="Blackman M" first="Marcia A." last="Blackman">Marcia A. Blackman</name><affiliation wicri:level="1"><nlm:aff id="af005">Trudeau Institute, Saranac Lake, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Trudeau Institute, Saranac Lake, NY</wicri:regionArea></affiliation></author><author><name sortKey="Marchionni, Mark A" sort="Marchionni, Mark A" uniqKey="Marchionni M" first="Mark A." last="Marchionni">Mark A. Marchionni</name><affiliation wicri:level="1"><nlm:aff id="af005">Trudeau Institute, Saranac Lake, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Trudeau Institute, Saranac Lake, NY</wicri:regionArea></affiliation></author><author><name sortKey="Gilly, John" sort="Gilly, John" uniqKey="Gilly J" first="John" last="Gilly">John Gilly</name><affiliation wicri:level="1"><nlm:aff id="af005">Trudeau Institute, Saranac Lake, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Trudeau Institute, Saranac Lake, NY</wicri:regionArea></affiliation></author><author><name sortKey="Hepburn, Matthew" sort="Hepburn, Matthew" uniqKey="Hepburn M" first="Matthew" last="Hepburn">Matthew Hepburn</name><affiliation wicri:level="1"><nlm:aff id="af010">Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA), Arlington, VA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA), Arlington, VA</wicri:regionArea></affiliation></author><author><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L." last="Innis">Bruce L. Innis</name><affiliation wicri:level="1"><nlm:aff id="af015">PATH, Washington, DC, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Washington, DC</wicri:regionArea></affiliation></author><author><name sortKey="Barrett, Alan D T" sort="Barrett, Alan D T" uniqKey="Barrett A" first="Alan D. T." last="Barrett">Alan D. T. Barrett</name><affiliation wicri:level="1"><nlm:aff id="af020">Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Kester, Kent E" sort="Kester, Kent E" uniqKey="Kester K" first="Kent E." last="Kester">Kent E. Kester</name><affiliation wicri:level="1"><nlm:aff id="af025">Sanofi Pasteur, Swiftwater, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanofi Pasteur, Swiftwater, PA</wicri:regionArea></affiliation></author><author><name sortKey="Mascola, John R" sort="Mascola, John R" uniqKey="Mascola J" first="John R." last="Mascola">John R. Mascola</name><affiliation wicri:level="1"><nlm:aff id="af030">Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Cummings, James F" sort="Cummings, James F" uniqKey="Cummings J" first="James F." last="Cummings">James F. Cummings</name><affiliation wicri:level="1"><nlm:aff id="af035">ICON Government and Public Health Solutions, Washington, D.C., USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>ICON Government and Public Health Solutions, Washington, D.C.</wicri:regionArea></affiliation></author><author><name sortKey="Monath, Thomas P" sort="Monath, Thomas P" uniqKey="Monath T" first="Thomas P." last="Monath">Thomas P. Monath</name><affiliation wicri:level="1"><nlm:aff id="af040">Crozet BioPharma LLC, Devens, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crozet BioPharma LLC, Devens, MA</wicri:regionArea></affiliation></author><author><name sortKey="Cassetti, M Cristina" sort="Cassetti, M Cristina" uniqKey="Cassetti M" first="M. Cristina" last="Cassetti">M. Cristina Cassetti</name><affiliation wicri:level="1"><nlm:aff id="af045">Virology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Virology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Jerome H" sort="Kim, Jerome H" uniqKey="Kim J" first="Jerome H." last="Kim">Jerome H. Kim</name><affiliation wicri:level="1"><nlm:aff id="af050">International Vaccine Institute, Seoul, South Korea</nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>International Vaccine Institute, Seoul</wicri:regionArea></affiliation></author><author><name sortKey="Saville, Melanie" sort="Saville, Melanie" uniqKey="Saville M" first="Melanie" last="Saville">Melanie Saville</name><affiliation wicri:level="1"><nlm:aff id="af055">Coalition for Epidemic Preparedness Innovations (CEPI), London, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Coalition for Epidemic Preparedness Innovations (CEPI), London</wicri:regionArea></affiliation></author><author><name sortKey="Thomas, Stephen J" sort="Thomas, Stephen J" uniqKey="Thomas S" first="Stephen J." last="Thomas">Stephen J. Thomas</name><affiliation wicri:level="1"><nlm:aff id="af060">Division of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31500964</idno><idno type="pmc">7131820</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131820</idno><idno type="RBID">PMC:7131820</idno><idno type="doi">10.1016/j.vaccine.2019.08.061</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000930</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000930</idno><idno type="wicri:Area/Pmc/Curation">000930</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000930</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases</title><author><name sortKey="Blackman, Marcia A" sort="Blackman, Marcia A" uniqKey="Blackman M" first="Marcia A." last="Blackman">Marcia A. Blackman</name><affiliation wicri:level="1"><nlm:aff id="af005">Trudeau Institute, Saranac Lake, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Trudeau Institute, Saranac Lake, NY</wicri:regionArea></affiliation></author><author><name sortKey="Marchionni, Mark A" sort="Marchionni, Mark A" uniqKey="Marchionni M" first="Mark A." last="Marchionni">Mark A. Marchionni</name><affiliation wicri:level="1"><nlm:aff id="af005">Trudeau Institute, Saranac Lake, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Trudeau Institute, Saranac Lake, NY</wicri:regionArea></affiliation></author><author><name sortKey="Gilly, John" sort="Gilly, John" uniqKey="Gilly J" first="John" last="Gilly">John Gilly</name><affiliation wicri:level="1"><nlm:aff id="af005">Trudeau Institute, Saranac Lake, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Trudeau Institute, Saranac Lake, NY</wicri:regionArea></affiliation></author><author><name sortKey="Hepburn, Matthew" sort="Hepburn, Matthew" uniqKey="Hepburn M" first="Matthew" last="Hepburn">Matthew Hepburn</name><affiliation wicri:level="1"><nlm:aff id="af010">Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA), Arlington, VA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA), Arlington, VA</wicri:regionArea></affiliation></author><author><name sortKey="Innis, Bruce L" sort="Innis, Bruce L" uniqKey="Innis B" first="Bruce L." last="Innis">Bruce L. Innis</name><affiliation wicri:level="1"><nlm:aff id="af015">PATH, Washington, DC, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>PATH, Washington, DC</wicri:regionArea></affiliation></author><author><name sortKey="Barrett, Alan D T" sort="Barrett, Alan D T" uniqKey="Barrett A" first="Alan D. T." last="Barrett">Alan D. T. Barrett</name><affiliation wicri:level="1"><nlm:aff id="af020">Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX</wicri:regionArea></affiliation></author><author><name sortKey="Kester, Kent E" sort="Kester, Kent E" uniqKey="Kester K" first="Kent E." last="Kester">Kent E. Kester</name><affiliation wicri:level="1"><nlm:aff id="af025">Sanofi Pasteur, Swiftwater, PA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Sanofi Pasteur, Swiftwater, PA</wicri:regionArea></affiliation></author><author><name sortKey="Mascola, John R" sort="Mascola, John R" uniqKey="Mascola J" first="John R." last="Mascola">John R. Mascola</name><affiliation wicri:level="1"><nlm:aff id="af030">Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author><author><name sortKey="Cummings, James F" sort="Cummings, James F" uniqKey="Cummings J" first="James F." last="Cummings">James F. Cummings</name><affiliation wicri:level="1"><nlm:aff id="af035">ICON Government and Public Health Solutions, Washington, D.C., USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>ICON Government and Public Health Solutions, Washington, D.C.</wicri:regionArea></affiliation></author><author><name sortKey="Monath, Thomas P" sort="Monath, Thomas P" uniqKey="Monath T" first="Thomas P." last="Monath">Thomas P. Monath</name><affiliation wicri:level="1"><nlm:aff id="af040">Crozet BioPharma LLC, Devens, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Crozet BioPharma LLC, Devens, MA</wicri:regionArea></affiliation></author><author><name sortKey="Cassetti, M Cristina" sort="Cassetti, M Cristina" uniqKey="Cassetti M" first="M. Cristina" last="Cassetti">M. Cristina Cassetti</name><affiliation wicri:level="1"><nlm:aff id="af045">Virology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Virology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD</wicri:regionArea></affiliation></author><author><name sortKey="Kim, Jerome H" sort="Kim, Jerome H" uniqKey="Kim J" first="Jerome H." last="Kim">Jerome H. Kim</name><affiliation wicri:level="1"><nlm:aff id="af050">International Vaccine Institute, Seoul, South Korea</nlm:aff><country xml:lang="fr">Corée du Sud</country><wicri:regionArea>International Vaccine Institute, Seoul</wicri:regionArea></affiliation></author><author><name sortKey="Saville, Melanie" sort="Saville, Melanie" uniqKey="Saville M" first="Melanie" last="Saville">Melanie Saville</name><affiliation wicri:level="1"><nlm:aff id="af055">Coalition for Epidemic Preparedness Innovations (CEPI), London, UK</nlm:aff><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Coalition for Epidemic Preparedness Innovations (CEPI), London</wicri:regionArea></affiliation></author><author><name sortKey="Thomas, Stephen J" sort="Thomas, Stephen J" uniqKey="Thomas S" first="Stephen J." last="Thomas">Stephen J. Thomas</name><affiliation wicri:level="1"><nlm:aff id="af060">Division of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY</wicri:regionArea></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><idno type="eISSN">1873-2518</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Li, Y" uniqKey="Li Y">Y. Li</name></author><author><name sortKey="Xu, C" uniqKey="Xu C">C. Xu</name></author><author><name sortKey="Ma, T" uniqKey="Ma T">T. Ma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, Y" uniqKey="Li Y">Y. Li</name></author><author><name sortKey="Muffat, J" uniqKey="Muffat J">J. Muffat</name></author><author><name sortKey="Omer, A" uniqKey="Omer A">A. Omer</name></author><author><name sortKey="Bosch, I" uniqKey="Bosch I">I. Bosch</name></author><author><name sortKey="Lancaster, M A" uniqKey="Lancaster M">M.A. Lancaster</name></author><author><name sortKey="Sur, M" uniqKey="Sur M">M. Sur</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, R" uniqKey="Li R">R. Li</name></author><author><name sortKey="Sun, L" uniqKey="Sun L">L. Sun</name></author><author><name sortKey="Fang, A" uniqKey="Fang A">A. Fang</name></author><author><name sortKey="Li, P" uniqKey="Li P">P. Li</name></author><author><name sortKey="Wu, Q" uniqKey="Wu Q">Q. Wu</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Graham, B S" uniqKey="Graham B">B.S. Graham</name></author><author><name sortKey="Sullivan, N J" uniqKey="Sullivan N">N.J. Sullivan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Szaba, F M" uniqKey="Szaba F">F.M. Szaba</name></author><author><name sortKey="Tighe, M" uniqKey="Tighe M">M. Tighe</name></author><author><name sortKey="Kummer, L W" uniqKey="Kummer L">L.W. Kummer</name></author><author><name sortKey="Lanzer, K G" uniqKey="Lanzer K">K.G. Lanzer</name></author><author><name sortKey="Ward, J M" uniqKey="Ward J">J.M. Ward</name></author><author><name sortKey="Lanthier, P" uniqKey="Lanthier P">P. Lanthier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeitlin, L" uniqKey="Zeitlin L">L. Zeitlin</name></author><author><name sortKey="Geisbert, J B" uniqKey="Geisbert J">J.B. Geisbert</name></author><author><name sortKey="Deer, D J" uniqKey="Deer D">D.J. Deer</name></author><author><name sortKey="Fenton, K A" uniqKey="Fenton K">K.A. Fenton</name></author><author><name sortKey="Bohorov, O" uniqKey="Bohorov O">O. Bohorov</name></author><author><name sortKey="Bohorova, N" uniqKey="Bohorova N">N. Bohorova</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diakite, I" uniqKey="Diakite I">I. Diakite</name></author><author><name sortKey="Mooring, E Q" uniqKey="Mooring E">E.Q. Mooring</name></author><author><name sortKey="Velasquez, G E" uniqKey="Velasquez G">G.E. Velasquez</name></author><author><name sortKey="Murray, M B" uniqKey="Murray M">M.B. Murray</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ebola Ca Suffit Ring Vaccination Trial Consortium" uniqKey="Ebola Ca Suffit Ring Vaccination Trial Consortium">Ebola ca Suffit Ring Vaccination Trial Consortium</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, X F" uniqKey="Li X">X.F. Li</name></author><author><name sortKey="Zhao, W" uniqKey="Zhao W">W. Zhao</name></author><author><name sortKey="Lin, F" uniqKey="Lin F">F. Lin</name></author><author><name sortKey="Ye, Q" uniqKey="Ye Q">Q. Ye</name></author><author><name sortKey="Wang, H J" uniqKey="Wang H">H.J. Wang</name></author><author><name sortKey="Yang, D" uniqKey="Yang D">D. Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Petrovsky, N" uniqKey="Petrovsky N">N. Petrovsky</name></author><author><name sortKey="Larena, M" uniqKey="Larena M">M. Larena</name></author><author><name sortKey="Siddharthan, V" uniqKey="Siddharthan V">V. Siddharthan</name></author><author><name sortKey="Prow, N A" uniqKey="Prow N">N.A. Prow</name></author><author><name sortKey="Hall, R A" uniqKey="Hall R">R.A. Hall</name></author><author><name sortKey="Lobigs, M" uniqKey="Lobigs M">M. Lobigs</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sun, E" uniqKey="Sun E">E. Sun</name></author><author><name sortKey="Zhao, J" uniqKey="Zhao J">J. Zhao</name></author><author><name sortKey="Taoyang, Xu Q" uniqKey="Taoyang X">Xu.Q. TaoYang</name></author><author><name sortKey="Qin, Y" uniqKey="Qin Y">Y. Qin</name></author><author><name sortKey="Wang, W" uniqKey="Wang W">W. Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Partidos, C D" uniqKey="Partidos C">C.D. Partidos</name></author><author><name sortKey="Paykel, J" uniqKey="Paykel J">J. Paykel</name></author><author><name sortKey="Weger, J" uniqKey="Weger J">J. Weger</name></author><author><name sortKey="Borland, E M" uniqKey="Borland E">E.M. Borland</name></author><author><name sortKey="Powers, A M" uniqKey="Powers A">A.M. Powers</name></author><author><name sortKey="Seymour, R" uniqKey="Seymour R">R. Seymour</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="other"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccine</journal-id><journal-id journal-id-type="iso-abbrev">Vaccine</journal-id><journal-title-group><journal-title>Vaccine</journal-title></journal-title-group><issn pub-type="ppub">0264-410X</issn><issn pub-type="epub">1873-2518</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31500964</article-id><article-id pub-id-type="pmc">7131820</article-id><article-id pub-id-type="publisher-id">S0264-410X(19)31137-5</article-id><article-id pub-id-type="doi">10.1016/j.vaccine.2019.08.061</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Blackman</surname><given-names>Marcia A.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Marchionni</surname><given-names>Mark A.</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Gilly</surname><given-names>John</given-names></name><xref rid="af005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Hepburn</surname><given-names>Matthew</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Innis</surname><given-names>Bruce L.</given-names></name><xref rid="af015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au030"><name><surname>Barrett</surname><given-names>Alan D.T.</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au035"><name><surname>Kester</surname><given-names>Kent E.</given-names></name><xref rid="af025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au040"><name><surname>Mascola</surname><given-names>John R.</given-names></name><xref rid="af030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au045"><name><surname>Cummings</surname><given-names>James F.</given-names></name><xref rid="af035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au050"><name><surname>Monath</surname><given-names>Thomas P.</given-names></name><xref rid="af040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au055"><name><surname>Cassetti</surname><given-names>M. Cristina</given-names></name><xref rid="af045" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au060"><name><surname>Kim</surname><given-names>Jerome H.</given-names></name><xref rid="af050" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au065"><name><surname>Saville</surname><given-names>Melanie</given-names></name><xref rid="af055" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au070"><name><surname>Thomas</surname><given-names>Stephen J.</given-names></name><xref rid="af060" ref-type="aff">l</xref><xref rid="cor1" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="af005"><label>a</label>Trudeau Institute, Saranac Lake, NY, USA</aff><aff id="af010"><label>b</label>Biological Technologies Office, Defense Advanced Research Projects Agency (DARPA), Arlington, VA, USA</aff><aff id="af015"><label>c</label>PATH, Washington, DC, USA</aff><aff id="af020"><label>d</label>Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA</aff><aff id="af025"><label>e</label>Sanofi Pasteur, Swiftwater, PA, USA</aff><aff id="af030"><label>f</label>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA</aff><aff id="af035"><label>g</label>ICON Government and Public Health Solutions, Washington, D.C., USA</aff><aff id="af040"><label>h</label>Crozet BioPharma LLC, Devens, MA, USA</aff><aff id="af045"><label>i</label>Virology Branch, Division of Microbiology and Infectious Diseases, NIAID, NIH, Rockville, MD, USA</aff><aff id="af050"><label>j</label>International Vaccine Institute, Seoul, South Korea</aff><aff id="af055"><label>k</label>Coalition for Epidemic Preparedness Innovations (CEPI), London, UK</aff><aff id="af060"><label>l</label>Division of Infectious Diseases, State University of New York, Upstate Medical University, Syracuse, NY, USA</aff><author-notes><corresp id="cor1"><label>⁎</label>Corresponding author.</corresp></author-notes><pub-date pub-type="pmc-release"><day>6</day><month>9</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><day>8</day><month>10</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>6</day><month>9</month><year>2019</year></pub-date><volume>37</volume><issue>43</issue><fpage>6248</fpage><lpage>6254</lpage><history><date date-type="received"><day>7</day><month>5</month><year>2019</year></date><date date-type="rev-recd"><day>22</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>8</month><year>2019</year></date></history><permissions><copyright-year>2019</copyright-year></permissions><abstract id="ab005"><p>Emerging and re-emerging infectious diseases are an expanding global threat to public health, security, and economies. Increasing populations, urbanization, deforestation, climate change, anti-vaccination movements, war, and international travel are some of the contributing factors to this trend. The recent Ebola, MERS-CoV, and Zika outbreaks demonstrated we are insufficiently prepared to respond with proven safe and effective countermeasures (i.e., vaccines and therapeutics). The State University of New York Upstate Medical University and the Trudeau Institute convened a summit of key opinion and thought leaders in the life sciences and biomedical research and development enterprises to explore global biopreparedness challenges, take an inventory of existing capabilities and capacities related to preparation and response, assess current “gaps,” and prospect what could be done to improve our position. Herein we describe the summit proceedings, “Translational Immunology Supporting Biomedical Countermeasure Development for Emerging Vector-borne Viral Diseases,” held October 2–3, 2018, at the Trudeau Institute in Saranac Lake, NY.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000930 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000930 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:7131820
|texte= Summit proceedings: Biomedical countermeasure development for emerging vector-borne viral diseases
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:31500964" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |